Full speed ahead with the wind at our back!
Recently, Shenzhen OxTium Biomedical Technology Co., Ltd. ("OxTium Technology") successfully completed a tens of millions RMB Angel+ round, led by Sequoia China Seed Fund.
OxTium Technology founder and CEO Jin Yongcheng stated that the funds from this round will be primarily used to further increase R&D investment in the frontier of AI life sciences, attract top talent, and comprehensively expand market presence, thereby continuously strengthening the core competitiveness of bioscience AI large models and application platforms.
Jin Yongcheng emphasized that the company's goal is to build a globally leading bioscience large model foundation, provide cutting-edge AI solutions, and accelerate breakthroughs in fundamental bioscience research and industrial applications worldwide.
Self-Developed GeneLLM Large Model: Strengthening the AI Foundation for Bioscience
One of OxTium Technology's core competencies lies in its self-developed GeneLLM bioscience AI large model.
This model is not a simple algorithmic stack, but a crystallization of deep learning and fusion of massive omics data (including transcriptome, genome, epigenome, metagenome, proteome, metabolome, etc.). GeneLLM directly analyzes raw sequencing data and outputs disease characterization correlation analysis end-to-end, avoiding error accumulation from hierarchical modeling, providing a novel and feasible technical pathway for bioscience research.
OxTium has successfully developed a 1.5 billion parameter version of GeneLLM, pre-trained on 23 billion sequencing reads and 3.45 trillion base pairs of data, endowing it with exceptional biological information understanding and prediction capabilities. In diagnostic applications for complex diseases such as Alzheimer's disease, six types of cancer, non-alcoholic steatohepatitis, and preterm birth, GeneLLM has demonstrated diagnostic accuracy far exceeding industry competitors, offering unprecedented possibilities for early disease detection and precise intervention.
Bioscience research is entering a new era.
The birth of OxTium's GeneLLM large model signifies a major advancement of AI in biology, widely applicable to fundamental research in disease diagnosis, drug development, synthetic biology, and more.
BioFord™ One-Stop Bioscience Research Platform: Transforming Bioscience Research Paradigms
Based on the powerful GeneLLM foundation, OxTium Technology has built the BioFord™ one-stop bioscience research platform, enabling researchers to perform model inference and fine-tuning with "zero code," fundamentally transforming bioscience research paradigms and rewriting research rules.
BioFord™ integrates cutting-edge model tools and practical AI functions. Based on advanced Transformer architecture and pre-trained on massive multi-omics data (RNA/DNA/protein/metabolome), it enables efficient multi-omics data modeling and feature mining. After fine-tuning, it supports fundamental research, medical diagnosis, biomanufacturing, breeding, environmental monitoring, and more, providing visual, high-precision, and interpretable multi-omics AI solutions.
Model Fine-Tuning Tool: A set of tools that empowers researchers with "customization" capabilities. Users can personalize existing models without training a large model from scratch, view model details, and manage fine-tuning tasks.
Model Inference Tool: Built-in specialized large models covering multiple biological subfields, enabling antibody missing sequence completion, nuclear instance segmentation and classification in multi-tissue pathology images, molecular simulation docking, etc., completing complex data analysis and predictions in a short time.
To meet the high standards of data privacy and security in scientific research, BioFord™ supports both cloud and local deployment simultaneously, with a built-in project-level data confidentiality management system. This solution not only fully ensures data integrity and confidentiality but also builds an efficient, collaborative, and secure research ecosystem, providing solid support for clinical and academic research in driving frontier breakthroughs and clinical translation.
AI4S Lab Digitalized Life Science Laboratory: "Super Brain and Butler"
This year, OxTium Technology also launched its self-developed AI4S Lab digitalized life science laboratory. Through intelligent operating systems, device management, consumable statistics, and scientific agent assistants, it achieves digital and automated management of the laboratory, greatly improving research efficiency and experimental quality.
Users can directly create experiment orders, issue commands through dialog boxes to automatically generate experimental designs, perform dry-lab model calls, automatically collect wet-lab data, and receive intelligent recommendations for consumables and restocking. Real-time monitoring during experiments provides a clear view of instrument operation.
With AI-driven plan generation, rapid experimental validation, and data feedback for optimization, OxTium's AI4S Lab acts like a "super brain" and "super butler," forming a full-chain intelligent closed loop from theoretical conception to experimental design and execution, from data analysis to autonomous iteration of experimental ideas.
As an AI solution provider, OxTium Technology has equipped AI4S Lab with over 10 representative models in general and bioscience vertical domains, while supporting custom import and deployment of various mainstream inference frameworks and models, providing a highly flexible development environment. It also includes over 15 high-quality multi-domain datasets available for researchers to download and use, promoting knowledge sharing and evolution.
AI4S Lab integrates OxTium's core technologies, evolving AI from a research aid into the core engine of scientific discovery, achieving a deep leap from "tool" to "ecosystem" reconstruction.
Capital Support Opens a New Chapter for AI for BioScience
The company has previously received investments from institutions such as Xiantong Capital and Leaguer Venture Capital, as well as tens of millions RMB in support from the Shenzhen High-Level Talent Special Fund. In R&D collaboration, it has established a Medical AI Research Center with Shenzhen Tsinghua Research Institute, formed close partnerships with industry benchmarks like BGI and Baidu PaddlePaddle, and worked with dozens of top-tier hospitals including Peking University First Hospital and Fudan University Shanghai Cancer Center to explore precision diagnosis and treatment solutions.
The investor in this round, Sequoia China Seed Fund, is the early-stage investment fund of globally renowned venture capital firm Sequoia Capital China, focusing on startups with disruptive innovation capabilities and huge growth potential, dedicated to discovering and supporting future industry leaders.
OxTium Technology brings together experts from top universities worldwide, including Oxford University, Peking University, and Beihang University, in fields such as bioinformatics, artificial intelligence, and biomedical engineering, demonstrating strong development strength and potential in technological innovation, market expansion, and industrial collaboration.
Looking ahead, OxTium Technology will continue to uphold its mission of "Exploring the Mysteries of Life with AI Technology," providing more efficient and intelligent solutions to global research institutions and industry partners, jointly opening a new chapter for AI for BioScience.
OxTium Technology's financing news has been covered by multiple media outlets including Arterial Network, 36Kr, ChinaVenture, and Investment World.